Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Impax Labs Inc (IPXL)

Impax Labs Inc (IPXL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,351,821
  • Shares Outstanding, K 73,870
  • Annual Sales, $ 775,790 K
  • Annual Income, $ -469,290 K
  • 60-Month Beta 1.15
  • Price/Sales 1.74
  • Price/Cash Flow N/A
  • Price/Book 7.25
  • Price/Earnings ttm 29.05
  • Earnings Per Share ttm 0.63
  • Most Recent Earnings 0.11 on 03/01/18
  • Next Earnings Date 05/09/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/18
See More
  • Average Estimate 0.16
  • Number of Estimates 5
  • High Estimate 0.22
  • Low Estimate 0.11
  • Prior Year 0.11
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.40 +5.17%
on 05/04/18
20.80 -12.02%
on 05/02/18
-1.45 (-7.34%)
since 04/04/18
3-Month
17.40 +5.17%
on 05/04/18
21.55 -15.08%
on 02/26/18
-1.10 (-5.67%)
since 02/02/18
52-Week
13.05 +40.23%
on 05/08/17
25.70 -28.79%
on 09/21/17
+5.10 (+38.64%)
since 05/04/17

Most Recent Stories

More News
LifeMax Receives Orphan Drug Designation From the European Commission for LM-030 for the Treatment of Netherton Syndrome

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating rare diseases with few or no therapeutic options, today announced that the European Commission granted orphan drug designation...

IPXL : 18.30 (unch)
NVS : 92.99 (-0.08%)
LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating rare diseases with few or no therapeutic options, today announced that the Food & Drug Administration (FDA) granted rare pediatric...

IPXL : 18.30 (unch)
NVS : 92.99 (-0.08%)
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Amneal Pharmaceuticals,...

IPXL : 18.30 (unch)
AMRX : 4.76 (-5.56%)
LifeMax Receives Orphan Drug Designation From the United States Food & Drug Administration For LM-030 For The Treatment of Netherton Syndrome

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating rare diseases with few or no therapeutic options, today announced that the Food & Drug Administration (FDA) granted orphan...

IPXL : 18.30 (unch)
NVS : 92.99 (-0.08%)
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Amneal...

IPXL : 18.30 (unch)
AMRX : 4.76 (-5.56%)
LifeMax Appoints Kathy LLampl, MD, as VP of Clinical Development

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating rare diseases with few or no therapeutic options, today announced the appointment of Kathy LLampl, MD, to the...

IPXL : 18.30 (unch)
Trade IPXL with:

Business Summary

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas,...

See More

Key Turning Points

2nd Resistance Point 19.77
1st Resistance Point 19.03
Last Price 18.30
1st Support Level 17.48
2nd Support Level 16.67

See More

52-Week High 25.70
Fibonacci 61.8% 20.87
Fibonacci 50% 19.38
Last Price 18.30
Fibonacci 38.2% 17.88
52-Week Low 13.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar